Clearpoint Neuro Stock News

Here are two interesting companies under $20.

Shares have lost 20% of their value since the initial public offering in February of last year. The company is well-positioned as a "picks and shovels" play to pharmaceutical partners addressing neuro

ClearPoint Neuro, Inc. (CLPT) delivered earnings and revenue surprises of 0% and 0.70%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

ClearPoint Neuro, Inc. (NASDAQ:CLPT ) Q2 2022 Earnings Conference Call August 9, 2022 4:30 PM ET Company Participants Joe Burnett - Chief Executive Officer Danilo D'Alessandro - Chief Financial Office

CLPT has been growing revenues steadily and has a large addressable market. It also has a very strong moat due to the nature of the FDA approval process.

ClearPoint Neuro, Inc. (CLPT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the

SOLANA BEACH, Calif., May 13, 2022 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the br

ClearPoint Neuro, Inc. (NASDAQ:CLPT ) Q1 2022 Earnings Conference Call May 11, 2022 4:30 PM ET Company Participants Joe Burnett - President & Chief Executive Officer Danilo D'Alessandro - Chief Financ

SOLANA BEACH, Calif., April 26, 2022 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the

SOLANA BEACH, Calif., March 29, 2022 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the

ClearPoint Neuro's (CLPT) CEO Joe Burnett on Q4 2021 Results - Earnings Call Transcript

Even though elective procedures are returning to the pre-pandemic level, the rise of the Omicron variant resurgence may continue to impact the case volume in the upcoming quarters. ClearPoint Neuro is

ClearPoint Neuro Inc (CLPT) shares closed today at 2.0% above its 52 week low of $10.10, giving the company a market cap of $243M. The stock is currently down 8.1% year-to-date, down 34.1% over the past 12 months, and up 796.5% over the past five years. This week, the Dow Jones Industrial Average fell 0.3%, and the S&P 500 fell 1.9%. Trading Activity Trading volume this week was 5.3% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.4. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and beats it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and beats it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and beats it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 75.7% The company's stock price performance over the past 12 months lags the peer average by 5.5% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

ClearPoint Neuro Inc (CLPT) shares closed today at 1.9% above its 52 week low of $10.12, giving the company a market cap of $249M. The stock is currently down 6.0% year-to-date, down 31.2% over the past 12 months, and up 817.4% over the past five years. This week, the Dow Jones Industrial Average fell 0.5%, and the S&P 500 fell 1.7%. Trading Activity Trading volume this week was 13.4% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.4. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and beats it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and beats it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and beats it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 126.6% The company's stock price performance over the past 12 months lags the peer average by 13.9% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

SOLANA BEACH, Calif., Jan. 05, 2022 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the b